SCHEMBL6602352

SCHEMBL6602352

CC(O)Cn1ccc2cc(Cl)c3ncccc3c21

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 14/20 0.78
HTR2C P28335 14/20 0.78
HTR2B P41595 13/20 0.78
L3MBTL1 Q9Y468 2/20 0.40
CCR1 P32246 1/20 0.40
CCR8 P51685 1/20 0.40
ALDH1A1 P00352 2/20 0.40
KDM4E B2RXH2 2/20 0.38
LMNA P02545 2/20 0.38
HSP90AA1 P07900 2/20 0.38
MAPT P10636 2/20 0.38
BRD4 O60885 1/20 0.38
METAP2 P50579 1/20 0.38
METAP1 P53582 1/20 0.38
MEN1 O00255 1/20 0.37
ALOX15B O15296 1/20 0.37
NR1I2 O75469 1/20 0.37
TP53 P04637 1/20 0.37
CYP3A4 P08684 1/20 0.37
HTR1A P08908 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6602349 1.00 HTR2A (0.78) HTR2AHTR2CHTR2BL3MBTL1CCR1
SCHEMBL906124 0.88 HTR2A (1.00) HTR2AHTR2CHTR2BL3MBTL1CCR1
Fumaric Acid SCHEMBL6603600 0.82 HTR2A (0.82) HTR2AHTR2CHTR2BL3MBTL1CYP3A4
Fumaric Acid SCHEMBL6603599 0.82 HTR2A (0.82) HTR2AHTR2CHTR2BL3MBTL1CYP3A4
Ammonia Solution, Strong SCHEMBL906126 0.80 HTR2A (0.70) HTR2AHTR2CHTR2BL3MBTL1CCR1
SCHEMBL6602404 0.77 HTR2A (0.76) HTR2AHTR2CHTR2BKDM4ELMNA
SCHEMBL4826871 0.77 HTR2A (0.76) HTR2AHTR2CHTR2BKDM4ELMNA
SCHEMBL4826880 0.77 HTR2A (0.76) HTR2AHTR2CHTR2BKDM4ELMNA
SCHEMBL906125 0.71 HTR2A (0.61) HTR2AHTR2CHTR2BL3MBTL1CCR1
SCHEMBL6604187 0.66 HTR2A (0.75) HTR2AHTR2CHTR2BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1109809-B1 PYRROLOQUINOLINES FOR TREATMENT OF OBESITY CEREBRUS PHARM LTD (GB) 2004-11-17 EP disclosed
US-6365598-B1 FOR THERAPY AND PROPHYLAXIS OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM; DAMAGE TO THE CENTRAL NERVOUS SYSTEM; CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; DIABETES INSIPIDUS; AND SLEEP APNEA VERNALIS RESEARCH LIMITED (GB) 2002-04-02 US disclosed